Vidaller A - Search Results

1

Cholesterol embolism: still an unrecognized entity with a high mortality rate.

Jucgla A, Moreso F, Muniesa C, Moreno A, Vidaller A. Jucgla A, et al. Among authors: vidaller a. J Am Acad Dermatol. 2006 Nov;55(5):786-93. doi: 10.1016/j.jaad.2006.05.012. Epub 2006 Jun 27. J Am Acad Dermatol. 2006. PMID: 17052483

2

Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients.

Sais G, Vidaller A, Jucglà A, Servitje O, Condom E, Peyri J. Sais G, et al. Among authors: vidaller a. Arch Dermatol. 1998 Mar;134(3):309-15. doi: 10.1001/archderm.134.3.309. Arch Dermatol. 1998. PMID: 9521029

3

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.

Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J. Sais G, et al. Among authors: vidaller a. Arch Dermatol. 1995 Dec;131(12):1399-402. Arch Dermatol. 1995. PMID: 7492128 Clinical Trial.

4

Tuberculous lymphadenitis presenting with cutaneous leucocytoclastic vasculitis.

Sais G, Vidaller A, Jucglà A, Peyrí J. Sais G, et al. Among authors: vidaller a. Clin Exp Dermatol. 1996 Jan;21(1):65-6. doi: 10.1046/j.1365-2230.1996.d01-162.x. Clin Exp Dermatol. 1996. PMID: 8689776

5

Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis. An immunohistologic and clinical study in 42 patients.

Sais G, Vidaller A, Jucglá A, Condom E, Peyrí J. Sais G, et al. Among authors: vidaller a. Arch Dermatol. 1997 Apr;133(4):443-50. Arch Dermatol. 1997. PMID: 9126007

6

Leukocytoclastic vasculitis and common variable immunodeficiency: successful treatment with intravenous immune globulin.

Sais G, Vidaller A, Servitje O, Jucglà A, Peyrí J. Sais G, et al. Among authors: vidaller a. J Allergy Clin Immunol. 1996 Jul;98(1):232-3. doi: 10.1016/s0091-6749(96)70247-6. J Allergy Clin Immunol. 1996. PMID: 8765839 No abstract available.

7

Antineutrophil cytoplasmic antibodies in leukocytoclastic vasculitis.

Sais G, Vidaller A, Jucglà A, Gallardo F, Peyri J. Sais G, et al. Among authors: vidaller a. Arch Dermatol. 1998 Feb;134(2):239-40. doi: 10.1001/archderm.134.2.239. Arch Dermatol. 1998. PMID: 9487220 No abstract available.

8

Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy.

Servitje O, Bordas X, Serón D, Vidaller A, Moreno A, Curcó N, Sais G, Peyrí J. Servitje O, et al. Among authors: vidaller a. J Cutan Pathol. 1996 Oct;23(5):431-6. doi: 10.1111/j.1600-0560.1996.tb01432.x. J Cutan Pathol. 1996. PMID: 8915851

Cyclosporin is a very effective treatment for severe psoriasis, but its exact mechanism of action in this disease is not completely understood. ...These results support the hypothesis that cyclosporin interferes with the expression of keratinocyte adhesion molecules in pat …

Cyclosporin is a very effective treatment for severe psoriasis, but its exact mechanism of action in this disease is not completely u …

9

Microscopic pulmonary tumoral embolism and subacute cor pulmonale as the first clinical signs of cancer.

Montero A, Vidaller A, Mitjavila F, Chivite D, Pujol R. Montero A, et al. Among authors: vidaller a. Acta Oncol. 1999;38(8):1116-8. doi: 10.1080/028418699432464. Acta Oncol. 1999. PMID: 10665773 Review. No abstract available.

10

Sarcoid pleural effusion: a report of two cases.

Salazar A, Mañá J, Corbella X, Vidaller A. Salazar A, et al. Among authors: vidaller a. Sarcoidosis. 1994 Sep;11(2):135-7. Sarcoidosis. 1994. PMID: 7809499

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters